Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;57(12):3199-204.
doi: 10.2337/db08-0649. Epub 2008 Oct 3.

Atrial natriuretic peptide induces postprandial lipid oxidation in humans

Affiliations

Atrial natriuretic peptide induces postprandial lipid oxidation in humans

Andreas L Birkenfeld et al. Diabetes. 2008 Dec.

Abstract

Objective: Atrial natriuretic peptide (ANP) regulates arterial blood pressure. In addition, ANP has recently been shown to promote human adipose tissue lipolysis through cGMP-mediated hormone-sensitive lipase activation. We hypothesized that ANP increases postprandial free fatty acid (FFA) availability and energy expenditure while decreasing arterial blood pressure.

Research design and methods: We infused human ANP (25 ng . kg(-1) . min(-1)) in 12 men (age 32 +/- 0.8 years, BMI 23.3 +/- 0.4 kg/m(2)) before, during, and 2 h after ingestion of a standardized high-fat test meal in a randomized, double-blind, cross-over fashion. Cardiovascular changes were monitored by continuous electrocardiogram and beat-by-beat blood pressure recordings. Metabolism was monitored through venous blood sampling, intramuscular and subcutaneous abdominal adipose tissue microdialysis, and indirect calorimetry.

Results: ANP infusion decreased mean arterial blood pressure by 4 mmHg during the postprandial phase (P < 0.01 vs. placebo). At the same time, ANP induced lipolysis systemically (P < 0.05 vs. placebo) and locally in subcutaneous abdominal adipose tissue (P < 0.0001 vs. placebo), leading to a 50% increase in venous glycerol (P < 0.01) and FFA (P < 0.05) concentrations compared with placebo. The increase in FFA availability with ANP was paralleled by a 15% increase in lipid oxidation rates (P < 0.05 vs. placebo), driving a substantial increase in postprandial energy expenditure (P < 0.05 vs. placebo).

Conclusions: Our data identify the ANP system as a novel pathway regulating postprandial lipid oxidation, energy expenditure, and concomitantly arterial blood pressure. The findings could have therapeutic implications.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Mean blood pressure (A) and heart rate (B) before and after ingestion of a test meal. On one day, subjects ingested the meal during a continuous ANP infusion; on another day, they ingested a meal during placebo (PLC) infusion. *P < 0.05 vs. baseline; **P < 0.01 vs. baseline; a, P < 0.05 ANP vs. placebo; b, P < 0.01 ANP vs. placebo. ○, ANP; •, PLC.
FIG. 2.
FIG. 2.
Venous insulin (A), glucose (B), FFAs (C), and glycerol (D) concentrations before and after ingestion of a high-fat test meal. On one day, subjects ingested the meal during a continuous ANP infusion; on another day, they ingested a meal during placebo (PLC) infusion. *P < 0.05 vs. baseline; **P < 0.01 vs. baseline; a, P < 0.05 ANP vs. placebo. ○, ANP; •, PLC.
FIG. 3.
FIG. 3.
Changes in microdialysis subcutaneous abdominal glycerol concentration (A) and skeletal muscle glycerol concentrations (B) before and after ingestion after a test meal. On one day, subjects ingested the meal during a continuous ANP infusion; on another day, they ingested a meal during placebo (PLC) infusion. *P < 0.05 vs. baseline; **P < 0.01 vs. baseline; a, P < 0.05 ANP vs. placebo. ○, ANP; •, PLC.
FIG. 4.
FIG. 4.
Changes in energy expenditure (A) and lipid oxidation rates (B) and relative changes in systemic β-hydroxybutyrate concentrations (C) with ANP or placebo (PLC) infusions. *P < 0.05 vs. baseline; **P < 0.01 vs. baseline; a, P < 0.05 ANP vs. placebo; b, P < 0.01 ANP vs. placebo. ○, ANP; •, PLC.

Similar articles

Cited by

References

    1. Hirsch J, Mackintosh RM, Aronne LJ: The effects of drugs used to treat obesity on the autonomic nervous system. Obes Res 8 :227 –233,2000 - PubMed
    1. Halpern A, Mancini MC: Treatment of obesity: an update on anti-obesity medications. Obes Rev 4 :25 –42,2003 - PubMed
    1. Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, Galitzky J: Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278 :48617 –48626,2003 - PubMed
    1. Sengenes C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumie A, Lafontan M, Galitzky J: Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol 283 :R257 –R265,2002 - PubMed
    1. Galitzky J, Sengenes C, Thalamas C, Marques MA, Senard JM, Lafontan M, Berlan M: The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. J Lipid Res 42 :536 –544,2001 - PubMed

Publication types